Last reviewed · How we verify
ABP 234
ABP 234 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.
ABP 234 is a RANKL inhibitor that blocks osteoclast activation and bone resorption. Used for Giant cell tumor of bone, Bone metastases.
At a glance
| Generic name | ABP 234 |
|---|---|
| Sponsor | Amgen |
| Drug class | RANKL inhibitor |
| Target | RANKL |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Oncology |
| Phase | Phase 3 |
Mechanism of action
ABP 234 targets RANKL (receptor activator of nuclear factor kappa-B ligand), a key mediator of osteoclast differentiation and activation. By inhibiting RANKL signaling, the drug reduces bone resorption and is being developed for conditions characterized by excessive bone loss or osteoclast-mediated pathology.
Approved indications
- Giant cell tumor of bone
- Bone metastases
Common side effects
- Hypocalcemia
- Osteonecrosis of the jaw
- Infection
Key clinical trials
- Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (PHASE3)
- A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |